CAR Therapies Could Offer New HBV, HIV Treatments

Why It Matters

CAR‑based immunotherapies could transform treatment of chronic viral infections, offering a potential pathway to functional cures that current antivirals cannot achieve. Demonstrating safety and sustained efficacy will be critical for attracting investment and advancing regulatory approval.

Key Takeaways

• CAR‑T/NK therapies cut HIV p24 and HBV DNA in preclinical models
• Early phase trials show modest, short‑lived antiviral effects with manageable side effects
• CAR‑NK cells may offer safer profile, lower risk of cytokine release syndrome
• Larger, longer‑term studies needed to achieve durable functional cures

Pulse Analysis

The success of chimeric antigen receptor (CAR) technology in hematologic cancers has spurred interest in repurposing these engineered cells for viral diseases. Researchers have adapted first‑generation CD3ζ constructs and second‑generation co‑stimulatory designs, even adding safety switches and bispecific targeting, to create CAR‑T and CAR‑NK platforms aimed at HIV and hepatitis B. By redirecting cytotoxic lymphocytes toward viral antigens, the approach seeks to eradicate infected cells that evade conventional antiretroviral or nucleos(t)ide therapies, a goal long pursued by virologists and immunologists alike.

The systematic review aggregated 21 in‑vitro, 14 in‑vivo, and eight early‑stage clinical studies, revealing consistent antiviral signals. Preclinical models reported standardized mean reductions of –1.15 for HIV p24 and –1.30 for HBV surface antigen, while in‑vivo experiments showed similar declines in viral RNA and DNA. Early human trials demonstrated modest drops in circulating HIV RNA and detectable HBV antigen suppression, with side‑effect profiles that were generally mild. Notably, CAR‑NK cells emerged as a potentially safer alternative, exhibiting lower incidence of cytokine release syndrome and reduced graft‑versus‑host risk.

Despite encouraging data, durability remains a hurdle; antiviral effects waned quickly, and toxicity—particularly with CAR‑T—poses a regulatory challenge. Experts advocate combining CAR therapies with latency‑reversing agents or immune modulators to prolong activity and target viral reservoirs. Larger, multi‑center trials with extended follow‑up are essential to validate efficacy, refine dosing, and establish safety benchmarks. If successful, virus‑directed CAR immunotherapies could reshape the chronic infectious disease market, opening new revenue streams for biotech firms and offering patients a functional cure beyond lifelong medication.